We studied the subcellular localization of MAD2 in normal human tissues and gastric cancers. MAD2 showed nuclear and cytoplasmic localization in normal tissues such as muscle, testis, thyroid gland, cerebrum, trachea, and skin; blood vessels In the cell division cycle, the localization and segregation of chromosomes is under the surveillance of a group of proteins called spindle assembly check proteins. 1-3 A number of check proteins have been identified in yeast and mammalian cells. [4] [5] [6] Among them, MAD2, a small protein (24 kDa) with no discernible catalytic domain, 7 is a key component of the MAD/BUB complex that can censor missegregation of chromosomes by monitoring the microtubule attachment and tension. 4, 7, 8 It is usually expressed at a high steady-state level and distributed at unattached kinetochores. MAD2 is vital for correct transferring of the genetic material into the progeny cells. 9,10 Once errors are detected, it causes cell cycle arrest at metaphase, and sufficient MAD2 will inhibit the onset of anaphase until all chromosomes exhibit proper bipolar attachment to the spindle and, thus, prevent the activation of the anaphase-promoting complex. 7, [11] [12] [13] [14] Defects in the spindle checkpoint could lead to mitotic nondisjunction and might be a cause of carcinogenesis. [15] [16] [17] [18] [19] Previous studies have indicated that an abnormality of MAD2 might lead to the failure of mitotic checkpoint function, but few mutations in the noncoding region of MAD2 have been noted in various types of cancers. 20-24 MAD2 overexpression has been described as a common event in variable malignancies such as malignant lymphoma and carcinomas of the liver, lung, and breast. 24, 25 Little is known about MAD2 expression in gastric cancer currently. In the present study, we investigated MAD2 expression in gastric cancer cell lines and tissues and attempted to elucidate the pathologic role of MAD2 in the development of gastric cancer by using tissue microarray.
We studied the subcellular localization of MAD2 in normal human tissues and gastric cancers. MAD2 showed nuclear and cytoplasmic localization in normal tissues such as muscle, testis, thyroid gland, cerebrum, trachea, and skin; blood vessels in some organs were also MAD2+. In normal stomach, MAD2 was expressed mainly in cytoplasm but showed nuclear staining in the majority of gastric cancers.
MAD2 was significantly overexpressed in gastric cancer compared with matched adjacent tissues (P < .001), and expression was related to differentiation and other clinical parameters of cancer (P < .001). The cancer/adjacent normal tissue (C/N) ratio of MAD2 expression was higher than 2 and more frequently observed in patients with lymph gland metastasis (P < .05) and related to cancer differentiation. Our findings suggest that the steady-state amount of MAD2 inside cells may serve as a molecular switch in mitotic checkpoint control and that the subcellular localizations of this spindle protein undergo a shift during malignant transformation. The change of MAD2 expression may be involved mainly in gastric carcinogenesis and associated with the prognosis of gastric cancer; a C/N of more than 2 may be associated with the worse prognosis for survival in gastric carcinoma.
In the cell division cycle, the localization and segregation of chromosomes is under the surveillance of a group of proteins called spindle assembly check proteins. [1] [2] [3] A number of check proteins have been identified in yeast and mammalian cells. [4] [5] [6] Among them, MAD2, a small protein (24 kDa) with no discernible catalytic domain, 7 is a key component of the MAD/BUB complex that can censor missegregation of chromosomes by monitoring the microtubule attachment and tension. 4, 7, 8 It is usually expressed at a high steady-state level and distributed at unattached kinetochores. MAD2 is vital for correct transferring of the genetic material into the progeny cells. 9, 10 Once errors are detected, it causes cell cycle arrest at metaphase, and sufficient MAD2 will inhibit the onset of anaphase until all chromosomes exhibit proper bipolar attachment to the spindle and, thus, prevent the activation of the anaphase-promoting complex. 7, [11] [12] [13] [14] Defects in the spindle checkpoint could lead to mitotic nondisjunction and might be a cause of carcinogenesis. [15] [16] [17] [18] [19] Previous studies have indicated that an abnormality of MAD2 might lead to the failure of mitotic checkpoint function, but few mutations in the noncoding region of MAD2 have been noted in various types of cancers. [20] [21] [22] [23] [24] MAD2 overexpression has been described as a common event in variable malignancies such as malignant lymphoma and carcinomas of the liver, lung, and breast. 24, 25 Little is known about MAD2 expression in gastric cancer currently. In the present study, we investigated MAD2 expression in gastric cancer cell lines and tissues and attempted to elucidate the pathologic role of MAD2 in the development of gastric cancer by using tissue microarray.
Materials and Methods

Patients and Tissue Specimens
We made 23 normal tissue microarrays from formalin-fixed, paraffin-embedded tissue blocks by using the Shanghai Superchip Tissue Microarray, Shanghai Superchip Biotech Company, Shanghai, China. Three cores from each tissue block were placed into the recipient paraffin block with a core size of 0.6 mm or 1.0 mm. Tissue samples from 102 gastric cancers and 102 normal gastric mucosae were obtained from patients who underwent surgery at the Department of General Surgery in Xijing Hospital (Xi'an, China). All cases of gastric cancer had been clinically and pathologically proven (data not shown). All patients who agreed to have their surgical tissues dissected for this study signed an informed consent form. The protocols used in the study were approved by the hospital's Protection of Human Subjects Committee. All authors carried out this research in accordance with the Helsinki Declaration.
Tissue Immunohistochemical Analysis
We made 4-µm sections of formalin-fixed paraffinembedded specimens. Specificities of commercially available antibodies directed against the MAD2 protein were evaluated by immunohistochemical analysis. After optimization of staining protocols, the best antibody concentration was selected for further investigation of the subcellular localization of MAD2 in normal tissue samples and their neoplastic counterparts.
Anti-MAD2 antibody (BD Biosciences, Franklin Lakes, NJ) was diluted to 1:150. Tissue sections were cut at 4 µm thick, mounted on SuperFrost glass slides (Menzel-Glaser, Braunschweig, Germany), and incubated at 56°C for 1 hour. Xylene-dewaxed paraffin sections were exposed to 0.5% hydrogen peroxide solution for 10 minutes to block endogenous peroxidase, rinsed in tap water for 5 minutes, and subjected to antigen retrieval in tris(hydroxymethyl)aminomethane (Tris)-EDTA buffer in a microwave oven. The oven was set to 800 W and the solution allowed to reach boiling, at which point the oven setting was reduced to 300 W to maintain a temperature of 85°C for an additional 20 minutes. After the sections were cooled to room temperature, they were incubated for 1 hour with the relevant antibodies diluted with antibody diluent (Ventana Medical Systems, Tucson, AZ). Slides were rinsed for 10 minutes in an immunohistochemical wash solution and incubated for 30 minutes with the horseradish peroxidase-labeled polymer conjugated secondary antibody (DakoCytomation, Carpinteria, CA). After rinsing for 10 minutes in the immunohistochemical wash solution, DAB (DakoCytomation) was applied as a substrate for 7 minutes, the slides were rinsed in distilled water for 10 minutes, counterstained with hematoxylin, and mounted.
A Nikon (Tokyo, Japan) Eclipse E 600 light microscope was used to evaluate the staining results. To determine the subcellular localization of each protein, 100 randomly selected, positive cells in each tissue were evaluated. If 90% of the cells showed nuclear staining, localization of the protein in question was said to be primarily nuclear. If the number of cells with nuclear and cytoplasmic staining exceeded 10%, the protein in question was localized to the nucleus and cytoplasm. Negative control slides using phosphate-buffered saline (PBS) as the primary antibody were included in all assays. A positive reaction was indicated by a reddish brown precipitate in the nucleus and cytoplasm.
Semiquantitative evaluation was used to determine cells with positive expression by viewing 10 vision fields at ×400 magnification. The ratio of positive cells per specimen was evaluated quantitatively as follows: -, staining of 10% or less of cells; 1+, staining of 11% to 25% of cells; 2+, staining of 26% to 50% of cells; 3+, staining of greater than 50% of cells. Two independent investigators scored all the sections without knowledge of patient outcome (double-blinded).
Cell Culture
Human gastric cancer cell lines AGS, MKN28, MKN45, SGC7901, MGC803, and KATOIII were cultivated in Dulbecco modified Eagle medium (Gibco RL, Grand Island, NY) supplemented with 10% fetal calf serum in a 37°C humidified incubator with a mixture of 95% air and 5% carbon dioxide (Forma Scientific/Thermo Scientific, Waltham, MA).
RNA Extraction and Semiquantitative Reverse Transcription-Polymerase Chain Reaction
The RNA of each cell line was extracted using Trizol (Life Technologies, Carlsbad, CA) according to the manufacturer's protocol. DNase was used to decrease the contamination of genomic DNA. The quantity and purity of the RNA prepared from each sample were determined by using UV absorbance spectroscopy. The reverse transcription reaction was performed using the First-Strand cDNA Synthesis Kit (Fermentas, Glen Burnie, MD) in a final volume of 20 µL. After incubation at 42°C for 60 minutes, the reverse transcription reaction was terminated by heating at 70°C for 10 minutes. The newly synthesized complementary DNA was amplified by polymerase chain reaction (PCR). The MAD2 primers were as follows: forward, 59-AAGGTGAAGGTCGGAGTCAA-39; reverse, 59-TGTGGTCATGAGTCCTTCCA-39. Amplification cycles were as follows: 95°C for 2 minutes; 36 cycles at 94°C for 30 seconds, 51°C for 45 seconds, and 72°C for 50 seconds; followed by 72°C for 10 minutes. β-actin primers (forward, 59-AGCGGGAAATCGTGCGTG-39; reverse, 59-CAGGG-TACATGGTGGTGCC-39) were used as an internal control. Aliquots of PCR product were electropho-resed on 1% agarose gels, and PCR fragments were visualized by ethidium bromide staining.
Western Blot Analysis
Cancer and its corresponding normal frozen tissue samples and gastric cell lines were prepared by the method described previously. 26 Briefly, tumor and nontumor specimens were ground into powder in the presence of liquid nitrogen. Around 0.5 g of tissue powder was resuspended in 1.5 mL of 10 mmol/L Tris-HCl, pH 7.8, 140 mmol/L sodium chloride, 5 g/L deoxycholate, 10 mL/L NP-40, 1 mmol/L phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 10 µg/mL pepstatin A, and 10 µg/mL leupeptin. The suspension was subjected to homogenization and further sonication on ice and finally was ultracentrifuged at 100,000g for 1 hour at 4°C. The supernatant was saved and assayed for protein concentration (Bradford method).
A measure of 30 µg of lysates was electrophoresed in 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted on a nitrocellulose membrane (Immoblin-P, Millipore, Bedford, MA). Membranes were blocked with 5% fat-free milk powder at room temperature for 2 hours and incubated overnight with a polyclonal antibody specific for rabbit anti-MAD2 (diluted 1:200; Santa Cruz Biotech, Santa Cruz, CA) or mouse anti-β-actin monoclonal antibody (diluted 1:2,000; Sigma, Swampscott, MA) at 4°C. After 3 washes for 15 minutes in Tris-buffered saline with 0.1% Tween-20 (TBST), the membrane was incubated with the horseradish peroxidaseconjugated goat antirabbit and goat antimouse secondary antibody (diluted 1:2,000; Santa Cruz Biotech, Santa Cruz, CA) for 1 hour at room temperature. The membrane was washed again in TBST 3 times and visualized by using the enhanced chemiluminescence system (Amersham Life Science, Piscataway, NJ).
Each experiment was performed in triplicate. All examined gene expression levels were quantitatively analyzed and expressed as ratios to β-actin.
Statistical Analysis
The SPSS version 13.0 software package (SPSS, Chicago, IL) was used for statistical data analysis. The Spearman rank correlation coefficients were used to identify significant correlations between the resultant gene expression patterns and histologic grade. The relationship between clinical variables was assessed by using the χ 2 or Fisher exact test, according to the categorization of the data. Statistical significance was achieved when the P value was less than .05.
Results
Subcellular Localization of MAD2 in Normal Tissues and Gastric Cancers
The positive signals of MAD2 protein were brown-yellow stains, and the strength of the color was directly proportional to positive percentages ❚Image 1❚ and ❚Image 2❚. We found detectable levels of MAD2 in the cytoplasm of 23 human normal tissues such as muscle, testis, thyroid gland, cerebrum, trachea, and skin. Half of these tissues, especially highly proliferating tissues, expressed MAD2 in the cytoplasm and nucleus. Subcellular localization of MAD2 remained nuclear and cytoplasmic in gastric cancers, and perinuclear staining was more evident. We also found that MAD2 was expressed mainly in the cytoplasm in gastric cancers but localized to the cytoplasm and nucleus in normal gastric tissues ❚Table 1❚.
Expression of MAD2 Up-Regulated in Human Gastric Cancer Cell Lines and Tissues
As shown in ❚Image 3❚, MAD2 messenger RNA and protein were detected in 1 moderately differentiated gastric cancer cell line (SGC7901), 4 poorly differentiated gastric cell lines (MKN28, MKN45, AGS, and KATOIII), and 1 well-differentiated gastric cancer cell line (MGC803). MAD2 expression in tumor and adjacent nontumor tissues from 102 patients with gastric cancer was analyzed by Western blot. As shown in ❚Image 4❚, MAD2 was detected in tumor and nontumor tissues. A patient with an elevated MAD2 level was defined as one whose MAD2 level in the tumorous tissue was higher than that in the adjacent nontumorous tissue, and the elevated MAD2 level could be found in human gastric cancer (P < .01). The differential MAD2 level was confirmed by comparison with the levels of β-actin in the same paired tissue lysates.
Elevated MAD2 Level and Clinicopathologic Characteristics
The relationship of an elevated MAD2 level with clinicopathologic characteristics was further investigated ❚Table 2❚. The evaluated parameters included factors such as age at diagnosis, sex, cell differentiation grade, and invasive and metastatic status. For the 102 studied patients, age and sex were not associated with higher levels of MAD2 in cancer tissues (P > .05). There was a significant difference in MAD2 expression among well, moderately, and poorly differentiated carcinomas (P < .001) ( Table 2 ). The expression of MAD2 was higher in lymph node metastatic gastric cancer. However, there was no relationship of nuclear expression between well-differentiated tumor tissues and moderately or poorly differentiated tissues (P > .05). But MAD2 expression in the nucleus in patients with lymph node metastasis was significantly higher than that in patients without lymph The relationship between MAD2 expression and metastasis of gastric cancer was further observed by Western blot (Image 4). It was found that the ratio of MAD2 protein in cancer tissues (C) to that in corresponding normal tissues (N) indicated that MAD2 expression in cancer tissues was approximately 2-fold higher than that in normal tissues. So we also analyzed the association between the C/N ratio of MAD2 expression and clinicopathologic parameters, including histologic differentiation and lymph node metastasis. The results showed that a C/N of more than 2 was significantly related to poorly differentiated gastric carcinomas and with lymph node metastasis (P < .05) ❚Table 4❚.
Discussion
Mitotic checkpoint proteins, especially MAD2, may be crucial for generating the "waiting" signal to prevent the onset of anaphase after microtubule disruption. 9, 27, 28 MAD2 is usually expressed at a high steady-state level and distributed at unattached kinetochores, 11, 18 and it can associate with and, thus, prevent the activation of anaphase-promoting complex. 7, 11, 12, 29 In our study, MAD2 was also found to be distributed diffusely in the cytoplasm in 23 human normal tissues studied by immunohistochemical analysis, and half of these tissues, especially highly proliferating tissues, expressed MAD2 in the cytoplasm and nucleus. We conclude that MAD2 has its primary subcellular localization in the cytoplasm and that the nuclear localization in some highly proliferating tissues may be linked to a higher protein translocation in proliferating cells. It is also presumed that cytoplasmic localization of MAD2 in normal tissues may be linked to a higher protein synthesis in proliferation with a reduced cell cycle.
Although the importance of MAD2 in mitotic checkpoint control has been elucidated in yeast and mammalian cells, the expression of MAD2 in human tissues and its association with human tumorigenesis are not fully understood. It was found that MAD2 gene mutations were rare in human cancers of bladder, 30 breast, 19, 31 digestive tract, 32 liver, 30 and lung. 33 Aberrantly reduced expression of MAD2 protein has been correlated with defective mitotic checkpoints in breast cancer 4 and NPC 34 cells. Furthermore, overexpression of MAD2 in transgenic mice led to a wide variety of neoplasia, broken chromosomes, anaphase bridges, and whole chromosome gains and losses, as well as acceleration of myc-induced lymphomagenesis, 35 suggesting that MAD2 overexpression and chromosome instability could be an important stimulus in the initiation and progression of different cancer subtypes. However, it is not clearly known whether the mitotic checkpoint is functional in gastric cancer cells.
To determine whether the mitotic checkpoint is functional in human gastric cancer, we used immunohistochemical node metastasis (P < .05), indicating that MAD2 expression in the nucleus might be increased in patients with gastric cancer with lymph node metastasis. No relation of MAD2 protein expression was found with the survival period after excision ❚Table 3❚.
MAD2 increased in gastric cancer cells, which may reflect increased expression of MAD2 that shifted to the nuclear membrane and the nucleus. Since translocation of cytoplasmic proteins into the nucleus in transformed cells is known, eg, the translocation of β-catenin from the cytoplasm into the nucleus is indicative of a disruption in the Wnt signal transduction pathway in a variety of cancers, 39, 40 we might speculate that a similar mechanism may be involved for the translocation of MAD2 to the nucleus in cancers. We presumed that MAD2 was activated by the lack of microtubule occupancy and currently was not linked to signaling pathways that had been activated by external stimuli. Previous studies have shown that aneuploid cancer cells have a robust spindle checkpoint, 41 and the transition of MAD2 into the nucleus could reflect an methods to elucidate some functions of MAD2. We found that 71% of patients with gastric cancer had elevated levels of MAD2 in their tumor tissues, and we found the expression of MAD2 was markedly increased in poorly differentiated gastric cancer, which provides in vivo evidence to support the hypothesis that up-regulation of certain mitotic checkpoint proteins has an important part in human tumorigenesis. It has been shown that MAD2 is localized to the cytoplasm, in agreement with immunohistochemical studies in mammary tissue, 36, 37 while in adenocarcinoma of the colon and stomach, MAD2 was localized to the cytoplasm when studied by immunohistochemical analysis. 18, 38 In our study, we found MAD2 was mainly localized to the cytoplasm in stomach tissues, and the perinuclear and nuclear staining of activated spindle checkpoint in aneuploid cells. However, preliminary data could not reveal any difference in the levels of MAD2 in aneuploid vs diploid cancers. More comprehensive studies are needed.
In this study, we provided the clinical data in detail to support the mitotic checkpoint role of MAD2 in gastric cancer tissues. We found that MAD2 messenger RNA and proteins were up-regulated in 6 gastric cancer cell lines (MKN28, MKN45, AGS, KATOIII, SGC7901, MGC803), and 71% of patients with gastric cancer had elevated levels of MAD2 in their tumor tissues. We speculated that the checkpoint activity of MAD2 exerted in these patients monitored the interaction of chromosomes, which is finally linked with better disease-free and overall survival, and this result coincided with the findings of a study in colon cancer that demonstrated that overexpression of MAD2 correlated with a poor prognosis. 42 An up-regulated level of MAD2 seems to be a possible hallmark of gastric cancer that is associated with aggressive tumor behavior and a poor prognosis.
However, there was no relationship of nuclear expression in well-differentiated tumor tissues and moderately or poorly differentiated tissue (P > .05). But MAD2 expression in the nucleus in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (P < .05), indicating that MAD2 expression in the nucleus might be increased in gastric cancer with lymph node metastasis.
The results showed that a C/N of more than 2 was significantly related to poorly differentiated gastric carcinomas and with lymph node metastasis (P < .05).Therefore, a C/N ratio of more than 2 may be clinically an important indicator for lymph node metastasis of gastric cancer.
The expression of MAD2 is related to histologic differentiation and lymph node metastasis of gastric cancer; in other words, the higher the protein level in gastric cancer tissues, the more poorly differentiated the tumor and the more frequent the lymph node metastasis. It was also first shown that MAD2 is expressed mainly in the nucleus in gastric cancers and localized mainly to the cytoplasm in gastric tissues. The shift of MAD2 from the cytoplasm to the nucleus takes part in gastric tumorigenesis. Therefore, these findings reveal that MAD2 might be a crucial marker of prognosis in gastric cancer and is a useful target when searching for an effective treatment against gastric cancer. 
